The Beat Is Real; the Repeat Belongs to Washington
Key Takeaways
- Revenue grew 9.6% to $19.161B and Adjusted EBITDA 18.5% to $3.870B, a genuinely excellent quarter. But roughly 40% of the $603M year-over-year EBITDA increase came from a $240M step-up in net Medicaid supplemental payments (Tennessee accruals plus newly approved grandfathered programs in Kansas and Texas), and another $50M is the easy comparison against last year's hurricane impact.
- Same-facility revenue per equivalent admission rose 6.6%, the strongest pricing print in recent quarters. Management attributed about half of that growth to the same supplemental programs, which puts underlying rate closer to 3% once payer mix, case mix and dispute-resolution recoveries are separated out.
- The full-year Adjusted EBITDA midpoint went up $450M, which management split as $250M supplemental and $200M operational. That is a candid disclosure, and it is also the ratio investors should apply to the headline beat.
- Management gave preliminary 2026 color on demand (2% to 3%) and cost trends (mostly stable) but explicitly declined to size the expiration of enhanced premium tax credits, with exchange equivalent admissions running up 8% in the quarter. The single largest 2026 variable is unquantified by design.
- Rating: Initiating at Hold. Execution is excellent and the balance sheet is doing real work, but the stock entered the print up 46.6% year to date within a dollar of its 52-week closing high, and the earnings base now carries a policy-timing component that neither management nor the Street will underwrite for 2026.
Results vs. Consensus
Q3 2025 Scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Revenue | $19.161B | $18.50B | Beat | +3.6% |
| Adjusted EBITDA | $3.870B | $3.48B | Beat | +11.2% |
| Adjusted EBITDA margin | 20.2% | n/a | Beat | +150bps YoY |
| EPS (GAAP, diluted) | $6.96 | n/a | Beat | +42.6% YoY |
| EPS (diluted, as adjusted) | $6.96 | $5.65 | Beat | +23.2% |
| Net income attributable to HCA | $1.643B | n/a | Beat | +29.4% YoY |
| Cash flow from operations | $4.416B | n/a | Beat | +25.6% YoY |
| Same-facility equivalent admissions | +2.4% | n/a | In line | Within 2–3% LT range |
GAAP and adjusted diluted EPS are identical at $6.96 this quarter because losses on sales of facilities rounded to $0.00 per share. Consensus marks shown where a published estimate exists; operating statistics and cash flow carry no comparable published estimate and are shown against the prior-year period.
Year-Over-Year Comparison
| $M except per share | Q3 2025 | % of rev | Q3 2024 | % of rev | YoY change |
|---|---|---|---|---|---|
| Revenues | $19,161 | 100.0% | $17,487 | 100.0% | +9.6% |
| Salaries and benefits | 8,364 | 43.6% | 7,861 | 45.0% | +6.4% / (140)bps |
| Supplies | 2,782 | 14.5% | 2,657 | 15.2% | +4.7% / (70)bps |
| Other operating expenses | 4,161 | 21.8% | 3,717 | 21.2% | +11.9% / +60bps |
| Equity in earnings of affiliates | (16) | (0.1%) | (15) | (0.1%) | +$1M income |
| Depreciation and amortization | 889 | 4.7% | 842 | 4.9% | +5.6% / (20)bps |
| Interest expense | 561 | 2.9% | 515 | 2.9% | +8.9% / flat |
| Losses on sales of facilities | 2 | n/a | 4 | n/a | n/a |
| Total costs and expenses | 16,743 | 87.4% | 15,581 | 89.1% | +7.5% / (170)bps |
| Income before income taxes | 2,418 | 12.6% | 1,906 | 10.9% | +26.9% / +170bps |
| Provision for income taxes | 515 | 2.7% | 424 | 2.4% | +21.5% |
| Net income | 1,903 | 9.9% | 1,482 | 8.5% | +28.4% |
| Net income attributable to NCI | 260 | 1.3% | 212 | 1.2% | +22.6% |
| Net income attributable to HCA | $1,643 | 8.6% | $1,270 | 7.3% | +29.4% |
| Diluted EPS | $6.96 | n/a | $4.88 | n/a | +42.6% |
| Diluted shares (M) | 236.181 | n/a | 259.917 | n/a | (9.1%) |
| Adjusted EBITDA | $3,870 | 20.2% | $3,267 | 18.7% | +18.5% / +150bps |
Quarter-Over-Quarter Comparison
| $M except per share | Q3 2025 | Q2 2025 | QoQ change |
|---|---|---|---|
| Revenues | $19,161 | $18,605 | +3.0% |
| Salaries and benefits (% of revenue) | 43.6% | 43.7% | (10)bps |
| Supplies (% of revenue) | 14.5% | 15.3% | (80)bps |
| Other operating expenses (% of revenue) | 21.8% | 20.4% | +140bps |
| Total costs and expenses (% of revenue) | 87.4% | 87.0% | +40bps |
| Income before income taxes | $2,418 | $2,415 | +0.1% |
| Net income attributable to HCA | $1,643 | $1,653 | (0.6%) |
| Diluted EPS | $6.96 | $6.83 | +1.9% |
| Diluted EPS, as adjusted | $6.96 | $6.84 | +1.8% |
| Diluted shares (M) | 236.181 | 241.911 | (2.4%) |
| Adjusted EBITDA | $3,870 | $3,849 | +0.5% |
| Adjusted EBITDA margin | 20.2% | 20.7% | (50)bps |
| Same-facility equivalent admissions (YoY) | +2.4% | +1.7% | +70bps accel. |
| Same-facility revenue per equiv. admission (YoY) | +6.6% | +4.0% | +260bps accel. |
The sequential table is where the quarter gets interesting, and it complicates the clean year-over-year story. Revenue grew 3.0% sequentially while Adjusted EBITDA grew 0.5%, so incremental margin on the sequential step was roughly 4%. Net income attributable to HCA actually declined 0.6% sequentially. Diluted EPS still rose 1.9%, entirely because the share count fell 2.4% on $2.498B of repurchases. That is the buyback doing the work, not the P&L.
- Revenue: The 9.6% growth decomposes into 3.2% reported equivalent admissions and 6.1% reported revenue per equivalent admission. Volume is fully organic and same-facility (2.4% equivalent admissions) sits inside the company's stated 2% to 3% long-term range. Pricing is the softer half: management said roughly half the same-facility rate growth of 6.6% came from Medicaid state supplemental payment revenue, with payer mix the next-largest contributor and dispute-resolution recoveries providing additional support.
- Margins: The 150bp Adjusted EBITDA margin expansion is real but assisted. Salaries and benefits fell 140bps as a percentage of revenue and supplies fell 70bps, both genuine operating leverage. Other operating expenses rose 60bps, which management attributed primarily to expenses associated with the Medicaid supplemental programs themselves and secondarily to professional fees. The supplemental programs therefore inflate both the revenue numerator and part of the cost base, and the net benefit ($240M year over year) is the number that matters.
- EPS: Of the 42.6% diluted EPS growth, 9.1 points of share-count reduction are pure capital allocation. The effective tax rate also fell to 21.3% from 22.2%, worth roughly 4 cents. Strip the buyback and the tax rate and operating EPS growth is closer to the high 20s, which still comfortably beats but is a different number than the headline.
- Cash: The cleanest line in the release. Operating cash flow of $4.416B against $1.288B of capital expenditures is strong even before noting that $1.3B of federal income tax payments were deferred into Q4 under IRS relief for Tennessee taxpayers. That deferral flatters the quarter and reverses next quarter.
Revenue assessment. Nine consecutive points of revenue growth is not the achievement here; the composition is. Same-facility equivalent admissions accelerated to 2.4% from 1.7% in Q2 despite what management described as a slow start to the respiratory season costing an estimated 50bps on admissions and 70bps on emergency room visits. Adjust for that and underlying demand ran near the top of the long-term range. The reported-versus-same-facility gap (3.2% versus 2.4% equivalent admissions) is acquisition contribution, consistent with the hospital count moving to 191 from 187. Nothing in the volume line looks borrowed or pulled forward.
Margin assessment. The labor line is the standout and it is the one investors should extrapolate. Salaries and benefits at 43.6% of revenue is the best ratio in recent memory, contract labor was flat year over year at 4.2% of total labor costs, and management explicitly said capacity is no longer staffing-constrained. That is a structurally different labor posture than the 2022 to 2023 period and it is not policy-dependent. Supplies at 14.5% reflects HealthTrust contract cycles and utilization management working as advertised. The offset is professional fees running 11% above prior year on a same-facility basis, concentrated in anesthesia and radiology, and now representing roughly 24% of total other operating expenses. That is the one cost line with no visible plan to converge toward inflation.
EPS assessment. HCA retired 6.514 million shares for $2.498B in the quarter and has reduced the diluted count 9.1% year over year. At a 16x earnings multiple, that repurchase is accretive on arithmetic alone, and with leverage in the lower half of the stated range the company has the capacity to keep doing it. The risk is not that the buyback is unwise; it is that a 42.6% EPS growth print built on 29.4% net income growth plus a 9.1% share reduction sets an anchoring expectation the operating business cannot meet once the supplemental payment comparisons turn.
Volume, Pricing and Payer Mix
HCA reports as a single operating segment, so the analytically useful decomposition is not by business line but by volume, rate and payer. The company's economics are the product of three things: how many equivalent admissions it takes, what it collects per equivalent admission, and which payer is on the other side of that admission. Q3 delivered on all three, with the third carrying an asterisk.
Reported vs. Same-Facility Operating Statistics
| Metric | Q3 2025 reported | Reported YoY | Q3 2025 same-facility | Same-facility YoY |
|---|---|---|---|---|
| Admissions | 577,804 | +2.8% | 567,382 | +2.1% |
| Equivalent admissions | 1,038,799 | +3.2% | 1,008,805 | +2.4% |
| Revenue per equivalent admission | $18,446 | +6.1% | $18,390 | +6.6% |
| Inpatient revenue per admission | $19,908 | +6.3% | $19,981 | +7.1% |
| Inpatient surgery cases | 138,563 | +2.0% | 136,467 | +1.4% |
| Outpatient surgery cases | 253,426 | +1.6% | 248,367 | +1.1% |
| Emergency room visits | 2,477,474 | +1.2% | 2,439,405 | +1.3% |
| Patient days | 2,692,513 | +0.1% | n/a | n/a |
| Average length of stay (days) | 4.660 | (0.127) days | n/a | n/a |
| Occupancy | 71.7% | (20)bps | n/a | n/a |
| Outpatient revenue as % of patient revenue | 38.3% | +10bps | n/a | n/a |
| Hospitals / freestanding surgery centers | 191 / 123 | +4 / (2) | n/a | n/a |
Assessment: The most underdiscussed number in the table is average length of stay falling to 4.660 days from 4.787, with patient days essentially flat (+0.1%) against admissions up 2.8%. HCA absorbed materially more patients without adding bed-days. Occupancy at 71.7% against weighted average beds in service of 42,896 means the physical constraint is not binding, and management said as much. This is the operational foundation that makes the 2026 volume commitment credible independent of what happens to coverage policy: the capacity to serve incremental demand exists, in both beds and staffing.
Payer Mix (same-facility equivalent admissions, YoY)
| Payer category | YoY change | Read |
|---|---|---|
| Total commercial | +3.7% | Highest-margin book growing fastest |
| of which: exchanges | +8.0% | The line most exposed to EPTC expiration |
| of which: commercial ex-exchanges | +2.4% | Employer-sponsored base growing with the market |
| Medicare | +3.4% | MA +4.8%, traditional +0.9% |
| Medicaid | +1.4% | Positive after several quarters of decline |
| Self-pay | (6.0%) | Uncompensated exposure shrinking |
This is as clean a payer-mix quarter as a hospital operator can print. Every commercially reimbursed category grew, self-pay shrank 6%, and Medicaid turned positive after multiple quarters of decline. Case mix index was up roughly 30bps year over year and down slightly sequentially, so the rate growth is not a coding-intensity artifact, a point management addressed directly when asked about industry commentary on utilization and coding.
"Regarding payer mix during the quarter, same-facility total commercial equivalent admissions increased 3.7% over prior year, with exchanges growing 8% and commercial, excluding exchanges, growing 2.4%. Medicare increased 3.4%, Medicaid increased 1.4% and self-pay declined 6%." — Mike Marks, CFO
Assessment: The mix is excellent and it is also the source of the 2026 risk. Exchange volumes growing 8% against total commercial at 3.7% means exchanges are contributing a disproportionate share of the fastest-growing, best-reimbursed category. If enhanced premium tax credits lapse and a portion of that book converts to self-pay or exits the system, HCA loses growth at the high end of the rate curve and gains volume at the bottom of it. The company does not disclose exchange revenue as a percentage of the total, which is precisely why the Street cannot size the exposure and why management's refusal to do so is consequential rather than merely cautious.
Service Line Color
Management volunteered an unusually granular read on which service lines moved. On the outpatient side, general surgery and urology were called out as strong; gynecology was slightly down. On the inpatient side, neurosciences, orthopedics and cardiac all grew; neurosurgery was modestly down. Outpatient payer mix was described as solid, with Medicaid and self-pay outpatient volumes below prior year, which mechanically improves outpatient revenue quality.
"Well, when we look at our outpatient surgery, we had strong general surgery activity. Our urological service line was very strong on the outpatient side. On the inpatient side, our neurosciences surgical capabilities, our orthopedic surgical capabilities, cardiac, all of these were up and had very good performance on a year-over-year basis." — Samuel Hazen, CEO
Assessment: The surgical acceleration is the detail worth carrying forward. Same-facility inpatient surgeries went from +0.5% in the first half to +1.4% in Q3, and outpatient from -0.5% to +1.1%. Surgical cases are the highest-contribution-margin volume HCA takes. A one-quarter inflection is not a trend, but combined with the length-of-stay improvement it suggests throughput initiatives are converting capacity into the right kind of case, not merely more cases.
Key KPIs
| KPI | Q3 2025 | Q2 2025 | Q3 2024 | Trend |
|---|---|---|---|---|
| Same-facility equivalent admissions growth | +2.4% | +1.7% | n/a | Accelerating |
| Same-facility revenue per equiv. admission growth | +6.6% | +4.0% | n/a | Accelerating (policy-assisted) |
| Adjusted EBITDA margin | 20.2% | 20.7% | 18.7% | Up YoY, down QoQ |
| Contract labor as % of total labor | 4.2% | n/a | ~4.2% | Flat and normalized |
| Same-facility professional fees growth | +11% | n/a | n/a | Running hot |
| Case mix index (YoY) | +30bps | n/a | n/a | Stable |
| Medicaid supplemental net benefit (YoY $) | +$240M | n/a | n/a | Step-function |
| Diluted shares outstanding (M) | 236.181 | 241.911 | 259.917 | Shrinking 9% YoY |
| Operating cash flow | $4.416B | n/a | $3.515B | +25.6% (tax-deferral aided) |
| Total debt | $44.511B | n/a | n/a | Leverage in lower half of target |
Key Topics & Management Commentary
Overall Management Tone: Confident on operations, deliberately non-committal on policy, and unusually forthcoming about the composition of its own beat. Management volunteered the supplemental-payment split of the guidance raise without being asked, quantified the year-over-year net benefit precisely, and repeatedly flagged the variability of the programs, which reads as an attempt to prevent the Street from capitalizing a policy windfall into the run rate. The one place the answers thinned was 2026, where every question that touched coverage policy was routed to the Q4 call.
1. Medicaid Supplemental Payments: $240M and a Pipeline Nobody Will Size
The dominant financial fact of the quarter. Net benefit to Adjusted EBITDA from Medicaid state supplemental payment programs increased approximately $240M year over year, driven by Tennessee program payments plus CMS approval of grandfathered applications in Kansas and Texas. The mechanics matter: Kansas is a calendar-year program, so nine months of impact was recorded in Q3; Texas contributed only one month; Tennessee was the largest single driver and the company both received cash and began accruing.
"So Tennessee was the largest driver of our net benefit in third quarter. We did receive cash in the third quarter of 2025, and we began accruing this program. So that's the update on Tennessee. Texas, as you know, we did receive approval of the grandfathered application. As this approval was really an enhancement to an existing program, this was really accrued just in our normal manner for third quarter of 2025." — Mike Marks, CFO
Management was careful to note the $240M is a net figure across a portfolio of programs with offsetting movements, not the sum of three approvals. Florida, Georgia and Virginia applications remain pending with CMS, and none of them are in guidance. Management said CMS is not expected to approve additional grandfathering during the government shutdown, though reviews are reportedly continuing.
Assessment: Nine months of Kansas recognized in one quarter is by definition out-of-period revenue, and Texas at one month means three quarters of run-rate accrual is still ahead. Both facts argue the Q3 number is not a clean run rate in either direction. The honest read is that the program base is structurally larger than it was a year ago and the quarterly recognition is lumpy. For modeling purposes the full-year net benefit guide ($250M to $350M favorable versus 2024) is the number to use, not the $240M quarterly delta.
2. The Enhanced Premium Tax Credit Cliff
Enhanced premium tax credits are scheduled to expire after December 31, 2025. The CEO addressed them in prepared remarks before any analyst raised the topic, which is itself a signal of how the company is ranking its risks. He framed HCA's position as advocacy rather than forecast.
"We continue to advocate strongly for the extension of this program for the 24 million Americans who depend on it for health insurance coverage. Today, we believe there is greater recognition by legislators of the negative impact this issue will have on families, small businesses and individuals than earlier in the year. At this point, however, we still do not know how this policy will play out." — Samuel Hazen, CEO
The company declined to size the impact three separate times, citing three unknowns: whether an extension happens, what form it takes, and the timing relative to open enrollment and any special enrollment period. Management did describe operational preparation, specifically expanded Parallon revenue-cycle financial-counseling resources to help patients navigate coverage transitions.
Assessment: The preparation is real and the refusal to guess is defensible. But an investor cannot underwrite a 2026 earnings number without a view on this, and the company has removed itself as a source of that view until late January. That is a three-month information vacuum on the largest single swing factor, during which the stock trades on other people's estimates of an exposure the company has never disclosed the size of.
3. Preliminary 2026: Demand and Costs Only
HCA customarily offers directional 2026 thoughts on the Q3 call. This year management explicitly narrowed that tradition, limiting preliminary commentary to demand and the cost environment and deferring everything else.
"Because of the fluid nature of the federal policy environment, we will limit our early thoughts for 2026 to our views on demand and the cost environment. We continue to see solid demand across our markets for health care services and believe volumes will be within our long-term 2% to 3% growth range. As it pertains to operating costs, we expect mostly stable trends consistent with the past couple of years." — Samuel Hazen, CEO
Pressed on how HCA gets to 2% to 3% volume growth in 2026 given that exchange growth carried a disproportionate share of 2025, the CEO leaned on the diversification argument and the track record rather than a bridge.
Assessment: The demand commitment is credible on capacity grounds (see the length-of-stay and occupancy discussion above) and on capital grounds, since management said more capital comes online in 2026 than in 2025. The cost commitment is the more valuable of the two, because a "mostly stable" cost environment paired with 2% to 3% volume is a mid-single-digit revenue algorithm that does not require policy help. What it does not do is defend the 2025 rate of growth, which is the number embedded in a stock up 46.6% year to date.
4. Labor: The Structural Win
Salaries and benefits fell to 43.6% of revenue from 45.0%, a 140bp improvement, with same-facility contract labor essentially flat year over year at 4.2% of total labor costs. Management was direct that the staffing-driven capacity constraints of two years ago are gone.
"If you recall from a couple of years ago, we had capacity constraints that were driven mostly by staffing and not having the workforce that we needed to take care of the patients who desired service in our facilities. We don't have that issue today. We've improved the net headcount of the company." — Samuel Hazen, CEO
Assessment: This is the highest-conviction piece of the operating story and the piece least dependent on Washington. Contract labor at 4.2% of total labor is a normalized level, and flat year-over-year growth in that line while volumes rise means the incremental patient is being served with permanent staff. If HCA holds this labor posture through a 2026 volume disruption, margin defense is far more achievable than in prior downturns.
5. Professional Fees: The Cost Line Running Hot
Same-facility professional fees grew 11% year over year and roughly 1% sequentially, concentrated in anesthesia and radiology. Professional fees represent approximately 24% of total other operating expenses on an as-reported basis, which makes an 11% growth rate a meaningful drag on the largest remaining cost bucket.
"So our same-facility professional fees increased 11% over the prior year in third quarter '25 versus third quarter '24. I'll note it's about a 1% sequential increase to second quarter of 2025. So professional fees continue to run hotter than just average inflationary levels across the rest of -- if you think about our cost structure, I might note that this is a bit more related to anesthesia and radiology this year." — Mike Marks, CFO
On Valesco, the emergency-physician and hospital-medicine staffing business HCA acquired, management declined to break out its contribution, describing it instead as an integrated part of the employee base and a strategic asset for case management and emergency room throughput. The CEO said continued financial improvement is expected in 2026 without committing to a number.
Assessment: Professional fees are the counterweight to the labor win and the reason "other operating expenses" rose 60bps year over year and 140bps sequentially. Two consecutive years of double-digit growth in a line worth roughly a quarter of other operating expenses is a structural cost problem, not a timing issue. The refusal to disclose Valesco's standalone economics, in a quarter where management disclosed the supplemental-payment split to the dollar, is a conspicuous asymmetry.
6. The Resiliency Program Becomes Permanent
The $600M to $800M resiliency target set at the November 2023 investor day was reframed on this call from a target to be hit into an ongoing program with a replenishing pipeline. Management described a develop-pilot-verify-scale loop, benchmarking, digital tooling, AI and machine-learning use cases, and expansion of shared-service platforms.
"We think about this as a program. In other words, as we have work streams that we identify, we work those through, we pilot them, we execute on them and then we roll them out to scale. And then literally, every day, we're hunting for new ideas." — Mike Marks, CFO
The CEO added a broader framing, extending resiliency beyond cost into organizational depth (succession planning, C-suite capability development) and network positioning (outpatient additions, throughput, competitive investment).
Assessment: Reframing a finite savings target as a perpetual program is a common way to avoid being held to the original number, and it deserves the skepticism that framing usually earns. The mitigating evidence is that core operating margin has genuinely improved since 2023, which the CEO pointed to directly. The test is whether resiliency shows up as margin defense when revenue growth decelerates, which is exactly the scenario 2026 may provide. Management committed to additional resiliency detail alongside 2026 guidance in January.
7. Hurricane Markets: A $100M Fourth-Quarter Hockey Stick
Management is holding to approximately $100M of Adjusted EBITDA growth in hurricane-affected markets for full-year 2025 versus 2024, against the roughly $250M hit those markets took in 2024. The problem is timing: through three quarters those markets are modestly below prior year, meaning effectively all of the $100M has to land in Q4.
"first quarter of 2025 was about flat to prior year. Second quarter was a bit negative, modestly negative in third quarter '25 to '24 combined for our hurricane markets on EBITDA was again about flat. So that's why we said in fourth quarter, we do expect that all plus of that $100 million improvement in year-over-year EBITDA will happen in the fourth quarter." — Mike Marks, CFO
The lingering damage is specific and unglamorous: North Carolina volumes have recovered but payer mix deteriorated, and the company is spending significant premium labor to staff those facilities.
Assessment: This is the softest assumption in the Q4 guide. A full-year target that requires 100% of the improvement in the final quarter, when the first three produced approximately zero, is a back-end-loaded assumption of the kind that usually gets revised. The offsetting consideration is that Q4 2024 was itself hurricane-depressed, so the comparison is genuinely easy. Investors should treat the $100M as the single most likely source of a Q4 shortfall against guidance.
8. Cash Conversion and the $1.3B Tax Deferral
Operating cash flow of $4.416B against Adjusted EBITDA of $3.870B is an unusual quarter, and the reason is disclosed: approximately $1.3B of estimated federal income tax payments were deferred year-to-date into Q4 under IRS relief granted to Tennessee taxpayers following severe weather in April. Asked about the structural improvement in EBITDA-to-free-cash-flow conversion from the 30% range toward the 40s and approaching 50% this year, management pointed to revenue-cycle execution through Parallon and working-capital management, and flagged the deferral explicitly.
"The other point, and I made this on the call, but it's important to note is that year-to-date, we have been able to defer $1.3 billion of estimated federal income tax payments to the fourth quarter." — Mike Marks, CFO
Assessment: Management flagged the distortion rather than letting the conversion ratio speak for itself, which is to their credit. The underlying working-capital story looks real: accounts receivable at $10.428B is below the $10.751B at December 31 despite revenue growing 9.6%, which is genuine collection improvement, not a one-time. But the free-cash-flow conversion figure investors have been extrapolating this year is roughly $1.3B too flattering, and it reverses in Q4.
9. Capital Allocation: $2.5B of Buyback in a Single Quarter
HCA repurchased 6.514 million shares for $2.498B in Q3, leaving $3.256B of authorization. Year-to-date repurchases total $7.509B against $4.342B in the prior-year period. The board declared a $0.72 quarterly dividend. Leverage remains in the lower half of the stated guidance range, and the company holds $6.076B of credit facility availability.
Asked about 2026 capital deployment, the CEO declined to pre-commit while signalling methodological continuity.
"I think it's a reasonable assumption to assume that our plan is going to be somewhat consistent with the methodologies we've used in the past. And so we need to get through the planning process that we're in now, see how some of the federal policies land." — Samuel Hazen, CEO
Assessment: Buying back 9.1% of the share count in twelve months at an average price well below the current quote has been value-accretive, and with leverage low the capacity to continue exists. The question this raises for 2026 is one of sequencing: if EPTC expiration compresses earnings, does HCA lean harder into buyback to defend EPS? Doing so would be defensible at a de-rated multiple and value-destructive at the current one. The answer arrives with January guidance.
10. Volume Streak and the Diversification Defense
Challenged on whether the 2% to 3% volume range is achievable in 2026 without exchange growth, the CEO fell back on the length of the record and the breadth of the portfolio.
"I realize the past is not prologue here, but we've had 18 consecutive quarters of volume growth. So that gives us a pretty confident foundation that we can continue to navigate through different dynamics within our markets." — Samuel Hazen, CEO
Separately, on the two of sixteen geographic divisions flagged as underperforming in Q2, one has recovered and one is still working through its issues, with management expressing confidence it will be where it needs to be entering 2026.
Assessment: Eighteen quarters is a real record and portfolio diversification is a real buffer, but the answer sidesteps the question that was asked. Without exchange growth, 2025 same-facility volume would have been below the long-term range, and pointing to a streak accumulated in a period of expanding coverage does not address a period of contracting coverage. This was the least satisfying answer on the call.
11. Utilization, Coding Intensity and AI
Managed-care commentary through 2025 has attributed cost pressure partly to provider coding intensity. Management pushed back with the case-mix index, which was up roughly 30bps year over year and down slightly sequentially, and said no material case-mix changes appeared at the individual line-of-insurance level. On AI, the near-term deployment is defensive rather than revenue-generating: revenue-cycle automation aimed at payer denials and underpayments, plus ambient documentation tools in pilot and rollout.
"It's always important to note, our coding practices remain consistent and accurate as verified by multiple layers of audits. Specifically related to AI, we do -- as Sam mentioned, we're deep into our efforts around digital transformation across our company, including in our revenue cycle. Our focus in terms of AI automation and our revenue cycle right now is really specifically focused on working to respond to the growing denial and underpayment activities from the payers." — Mike Marks, CFO
Assessment: The case-mix data supports the rebuttal, and a 30bp move is not the signature of coding-driven revenue inflation. More telling is the characterization of the payer relationship: HCA is deploying AI primarily to fight denials, and separately credited "improved dispute resolution results" as a contributor to rate growth this quarter. That describes an increasingly adversarial reimbursement environment in which a portion of revenue growth is recovered rather than earned, and recovery revenue has a ceiling.
Guidance & Outlook
| FY2025 metric | Prior low (Jul 25) | Prior high (Jul 25) | New low (Oct 24) | New high (Oct 24) | Change |
|---|---|---|---|---|---|
| Revenues | $74.000B | $76.000B | $75.000B | $76.500B | Raised (+$750M midpoint) |
| Net income attributable to HCA | $6.110B | $6.480B | $6.495B | $6.715B | Raised (+$310M midpoint) |
| Adjusted EBITDA | $14.700B | $15.300B | $15.250B | $15.650B | Raised (+$450M midpoint) |
| Diluted EPS | $25.50 | $27.00 | $27.00 | $28.00 | Raised (+$1.25 midpoint) |
| Capital expenditures | ~$5.0B | ~$5.0B | Maintained | ||
| Diluted shares (guidance basis) | n/a | 240.000M | n/a | ||
Management gave the composition of the raise without being asked, which is the disclosure that defines how this guide should be read.
"We are increasing our earnings guidance at the midpoint of adjusted EBITDA by $450 million. This represents an expected $250 million increase in net benefit from the state supplemental payment programs and $200 million increase from operational performance." — Mike Marks, CFO
Implied Q4 ramp. Nine-month revenue is $56.087B against a full-year guide of $75.000B to $76.500B, implying Q4 revenue of $18.913B to $20.413B (midpoint $19.663B, or +2.6% sequentially and roughly +7.5% year over year). Nine-month Adjusted EBITDA is $11.452B against a $15.250B to $15.650B guide, implying Q4 Adjusted EBITDA of $3.798B to $4.198B (midpoint $3.998B, or +3.3% sequentially). Management characterized the implied Q4 growth rate as "high single digits range, maybe 7% roughly" after accounting for the hurricane comparison and a $120M assumed decline in supplemental net benefit versus the prior-year quarter.
Street at. The consensus HCA beat this quarter ($5.65 EPS, ~$18.50B revenue) had not incorporated the Kansas and Texas approvals. The new EPS range of $27.00 to $28.00 against nine-month diluted EPS of $20.23 implies Q4 diluted EPS of roughly $6.77 to $7.77, a range wide enough to accommodate both the hurricane-market recovery landing and not landing.
Guidance style. Historically conservative and, on this quarter's evidence, still so in one specific respect: the guide explicitly excludes any impact from the Florida, Georgia and Virginia grandfathered applications pending at CMS. Management stated it will not size those until approved. The upside case for Q4 is therefore structurally unguided, while the downside case (hurricane markets) is structurally embedded. That asymmetry has historically favored the beat.
Analyst Q&A Highlights
Which Grandfathered State Applications Remain Pending, and What They Could Add
The opening question went straight to the largest unquantified upside in the model. Management named the pending states, confirmed CMS is unlikely to act during the government shutdown while reviews continue, and declined to size any of them, reiterating that guidance carries none of this.
Q: "Great. And thanks for all the detail on the DPP programs. Can you remind us -- I know there's other states that have preprints in for approval for grandfather programs. Can you remind us what states are still pending? And any quantification of what could be incremental would be great."
— Ann Hynes, Mizuho Securities
A: "So as you think about kind of the states, there are several that have applied under the grandfathering programs, we've mentioned Florida before and certainly, that one is under review. There are a few others as well. I might mention Georgia and Virginia as well being in that list. We do not expect that CMS will be approving these additional grandfathering programs during the shutdown."
— Mike Marks, CFO
Assessment: Naming Florida, Georgia and Virginia while refusing to quantify is the right disclosure posture and an uncomfortable modeling position. Florida is HCA's largest state by facility concentration, so an approval there would be material in a way the others would not. The optionality is real, unguided and entirely dependent on when the federal government reopens.
Why the Guidance Raise Was Smaller Than the Quarter's Beat
The most pointed challenge of the call: if the quarter beat by this much even excluding supplemental payments, why did the full-year midpoint move by so much less? Management's bridge was hurricane markets plus a declining supplemental comparison in Q4, landing on an implied growth rate it characterized as roughly 7%.
Q: "The quarter was a pretty strong beat even if we exclude the supplemental payments in the 3Q, but guidance didn't go up a whole lot past the beat you guys did this quarter, at least at the midpoint of the range. Can you give us any color on how we should think about the range of guidance implied on the fourth quarter, if we just steer towards one or the other?"
— Pito Chickering, Deutsche Bank
A: "When I think about fourth quarter growth rate, there's really 2 main considerations that I would think about and then the third being just operations. But the first would be the hurricane impact for sure. And then the second would be the decline in state supplemental payments that I noted in my comments when you compare fourth quarter of '25 to prior year. When we take those 2 factors into consideration, we believe the implied growth rate is still solid for fourth quarter in the kind of high single digits range, maybe 7% roughly."
— Mike Marks, CFO
Assessment: The answer is arithmetically coherent and still leaves the guide looking conservative, since the $120M assumed supplemental decline and the hurricane recovery are both explicitly in the numbers while the pending CMS approvals are not. Management's added note that the top of the range accommodates "even stronger performance" is the tell. This is a guide built to be beaten.
Whether Q4 Elective Volumes Will Be Pulled Forward Ahead of Coverage Loss
A recurring theme across the sector this quarter has been whether patients facing the loss of subsidised coverage will accelerate elective procedures into the fourth quarter. Management said it is not sizing the effect and described the three sequential unknowns that make it unsizable, while detailing the revenue-cycle infrastructure built to help patients navigate re-enrollment.
Q: "So there's been some chatter and some of the managed care companies are talking about anticipating a potential step-up in volumes in the fourth quarter, elective procedures, because people are worried that they're going to lose coverage or their co-pays and deductibles will go up dramatically. I wonder if you're seeing an early scheduling for surgeries, for example, elective surgeries or anything else that would indicate that we might see that in the fourth quarter."
— A.J. Rice
A: "I mean, right now, we're really not sizing the potential impact given the fact that it's so fluid. There's going to be an enrollment period, as you know, that opens up here in a couple of weeks. When we get to the fourth quarter call, A.J., we'll have a lot more information."
— Mike Marks, CFO
Assessment: Notable for what was absent: no observation of early elective scheduling either way. A company seeing a pull-forward build in its Q4 surgical schedule would likely have said so, since it would be a favorable near-term datapoint. The silence suggests the pull-forward is a sector narrative more than an HCA booking pattern so far, which removes a potential Q4 upside kicker.
Decomposing the Net Revenue per Equivalent Admission Growth
The pricing line was the quarter's most impressive number and drew a direct request to break it apart. Management ranked the drivers in order, and the ranking is unflattering to anyone extrapolating the headline.
Q: "First, I think you mentioned payment dispute resolution is one of the drivers of revenue growth, pricing growth in the quarter. How much of a benefit there? And then another question on DPP. It sounds like your DPP number for 2025 benefit will be somewhere in the -- if I'm right, the $2.3 billion, $2.4 billion range billion this year. Is that the right number?"
— Justin Lake, Wolfe Research
A: "When I think about our net revenue per equivalent admission growth, in the third quarter to prior year, first thing, and I mentioned this in them comments, Justin, but the first thing is about half of the growth was related to state supplemental payment increases in revenue. And so that's a piece. I also mentioned and it's the next biggest driver is payer mix. I mean, as we noted, with very strong payer mix in the quarter, and that's the next biggest driver for sure in our overall growth in net revenue per unit. Case mix index was pretty consistent."
— Mike Marks, CFO
Assessment: This exchange is the single most important disclosure of the call for modeling purposes. Half of a 6.6% same-facility rate increase is roughly 330bps of policy, leaving roughly 330bps of underlying rate from payer mix, dispute recoveries and a stable case mix. Underlying rate near 3% against volume near 2.4% is a mid-single-digit organic revenue algorithm, which is a good business and a materially different one than the 9.6% the tape just saw. Management also sidestepped the request to quantify the dispute-resolution benefit specifically.
How the Company Reaches 2% to 3% Volume Growth Without Exchange Expansion
The most analytically precise challenge of the call, and the one where the answer relied most on history. The questioner observed that stripping out exchange growth would have put 2025 volume below the long-term range, then asked what replaces it.
Q: "I'm wondering if there's something that you can speak to that gives you confidence in achieving the long-term volume range at this point. I guess the question would really just be without exchange growth, you'd be below the range this year. So I'm sure you thought about that even with an extension, exchange volumes could potentially be flat to down next year."
— Stephen Baxter, Wells Fargo
A: "I realize the past is not prologue here, but we've had 18 consecutive quarters of volume growth. So that gives us a pretty confident foundation that we can continue to navigate through different dynamics within our markets. As I mentioned, we have more capital coming online next year. We have more outpatient facilities. So our ambulatory outreach is growing."
— Samuel Hazen, CEO
Assessment: The premise of the question was not disputed, which is itself informative: management did not push back on the claim that ex-exchange volume growth would have been below range. The reply substituted capacity additions and track record for a bridge. Capacity is a necessary condition for volume growth, not a sufficient one, and in a coverage contraction the binding constraint is demand, not beds.
Tracking Against the $600M to $800M Resiliency Target
A question aimed at accountability against a specific number set at the 2023 investor day drew an answer that reframed the target as a perpetual pipeline rather than a milestone with a completion date.
Q: "On the $600 million to $800 million resiliency program you laid out a few years ago, can you just give us a sense on kind of how you're tracking to that? And then how you think about any additional levers to extend that further over time, whether that's technology or increased AI adoption?"
— Craig Hettenbach, Morgan Stanley
A: "So at our Investor Day back in 2023, we highlighted our resiliency plan, including that target of $600 million to $800 million. We've been working hard on that. And -- but the other thing that we highlighted, so yes, some of those dollars helped us in '24 and in '25 -- but as we've gone through really the last 12 to 18 months, we've been focused at both enhancing and accelerating our development of our resiliency program."
— Mike Marks, CFO
Assessment: No progress figure was given against a target the company itself quantified two years ago. The CEO's follow-on, pointing to core operating margin improvement since 2023 as evidence, is indirect but not unreasonable given the 150bp Adjusted EBITDA margin expansion this quarter. Still, a company willing to disclose a $240M supplemental-payment delta to the dollar should be able to state cumulative resiliency capture. The promised January update is the checkpoint.
Sustainability of the Step-Up in Cash Conversion
The final question of the call addressed the least-discussed and arguably most impressive trend: EBITDA-to-free-cash-flow conversion moving from roughly 30% into the 40s and approaching 50% this year. Management separated the structural drivers from the one-time one.
Q: "So I wanted to ask about cash flow conversion. We've seen the ratio of EBITDA that converts to free cash flow sort of move from the 30% range into the 40s. And I think this year, you're on track to almost 50%. So maybe talk about the factors that are driving that? Is that a shift to outpatient? Is there an impact from the strong pricing, including the sub payments? And I guess, most importantly, do you think that's sustainable over the next couple of years?"
— Joshua Raskin, Nephron Research
A: "There's 3 or 4 things I would note that are driving our strong cash flow from operations as we think about it. One certainly is just we've had really solid adjusted EBITDA growth. And that strong operational performance that we continue to highlight as we think about the strength of our revenue cycle operations with Parallon, we turn that revenue into cash."
— Mike Marks, CFO
Assessment: The answer led with EBITDA growth and working capital before disclosing the $1.3B tax deferral, which is the right substantive order but buries the one item that makes this year's ratio unrepeatable. Adjusting for the deferral, conversion is still improved versus history on genuine receivables performance. Investors modeling a sustained approach to 50% conversion are extrapolating a number that includes roughly $1.3B of timing.
What They're NOT Saying
- The size of the exchange book. HCA disclosed that exchange equivalent admissions grew 8%, but not what percentage of revenue or admissions the exchange population represents. Without that denominator, no one outside the company can size the EPTC exposure, which is the entire 2026 debate. This is the most consequential omission in the release.
- Any 2026 earnings framework. The company customarily offers directional next-year commentary on the Q3 call and this year restricted it to volume and cost trends. No revenue framework, no margin framework, no capital allocation plan. The deferral is justified by policy uncertainty, but it means the stock trades for three months on estimates the company has declined to anchor.
- The dispute-resolution contribution. Management named "improved dispute resolution results" as a driver of rate growth, was asked directly how much it was worth, and answered around it. Recovery revenue from payer disputes is inherently non-recurring at the individual-claim level, so its size matters for judging the durability of the 6.6% rate print.
- Valesco's standalone financials. Asked directly about Valesco's historical $40M to $50M quarterly EBITDA drag and the path to breakeven in 2026, management declined to break it out, calling it integrated into the employee base. In a quarter where the supplemental-payment delta was quantified to the dollar, this selective opacity is notable.
- Cumulative progress against the $600M to $800M resiliency target. Two years after setting it, no number. The program was reframed as ongoing, which conveniently removes the finish line against which progress would be measured.
- What the second underperforming division actually costs. Two of sixteen divisions were flagged in Q2; one recovered, one has not. No quantification of the drag in either direction, and no description of what the remaining problem is.
- Whether Q4 elective scheduling is showing a pull-forward. Asked whether early scheduling data showed patients accelerating procedures ahead of possible coverage loss, management said it was not sizing the impact and did not say whether it was seeing one. A company observing a favorable booking trend would generally say so.
Market Reaction
- Pre-print setup: HCA closed at $440.16 on October 23, up 46.6% year to date against the S&P 500 at +14.6%, up 10.3% over trailing twelve months and 5.7% over the trailing thirty days. The pre-print close sat within a dollar of the 52-week closing high of $441.19, against a 52-week closing low of $296.70. The stock entered the print priced for a good quarter.
- Reaction session (October 24, before-open reporter): Opened at $457.13, a 3.9% gap up, traded a wide $424.00 to $461.56 range (-3.7% to +4.9% versus the prior close), and closed at $447.04, up 1.6% or $6.88. The S&P 500 rose 0.8% the same session.
- Volume: 2.8 million shares against a 30-day average of 1.2 million, or 2.3x normal.
The intraday path is more informative than the close. A 23% EPS beat and an 11% Adjusted EBITDA beat opened the stock up 3.9%, then gave back more than the entire gap intraday (touching $424.00, which is 3.7% below the prior close) before settling up 1.6%. That is not a market rejecting the quarter. It is a market repricing the quarter's composition in real time as the call proceeded, specifically once management disclosed that $250 million of the $450 million guidance raise was supplemental payments and that roughly half the rate growth was the same.
The 2.3x volume with a round trip from +4.9% to -3.7% and back describes genuine two-way disagreement rather than a consensus verdict. Given a starting point at 52-week highs and a 46.6% year-to-date advance, the burden on this print was to justify the re-rating already achieved, not merely to beat. A 1.6% close on a 23% beat means the market judged it did not quite clear that bar, and the reason is legible in the guidance composition.
Street Perspective
Debate: Is the Supplemental Payment Benefit a New Base or a Timing Windfall?
Bull view: CMS approvals of grandfathered applications in Kansas and Texas expand the structural program base, not just this year's recognition. Three more states are pending, none in guidance, and the programs have been growing for several years. The right way to read $240M is as evidence the base has stepped up permanently.
Bear view: Nine months of Kansas recognized in a single quarter is the definition of out-of-period revenue, management itself guided to a $120M sequential decline in Q4 net benefit, and the programs are described by the company as complex and variable in timing. Capitalizing this into a multiple is exactly the error that gets punished when the comparison turns.
Our take: Both sides are partly right, which is why the full-year net benefit guide ($250M to $350M favorable versus 2024) is more useful than the quarterly delta. The base has genuinely stepped up; the quarterly recognition is genuinely lumpy. The correct adjustment is not to exclude supplemental payments but to refuse to grow them, and to note that a business whose earnings growth depends on an annually renegotiated state-federal payment mechanism deserves a lower multiple than one whose does not.
Debate: Does the EPTC Expiration Break the 2026 Algorithm?
Bull view: Exchange volumes are a small slice of a diversified book, HCA has built out revenue-cycle counseling to route displaced patients into Medicaid or replacement coverage, legislative recognition of the issue is improving, and an extension in some form remains the base case. Even a full lapse hits growth rate, not absolute earnings.
Bear view: Exchange volumes grew 8% against total commercial at 3.7%, so exchanges are carrying disproportionate weight in the highest-margin category. Displaced patients do not vanish; they return as self-pay through the emergency room at negative contribution margin, which is a double hit to mix. The company will not disclose the exposure, which is rarely because the number is small.
Our take: The bear framing on mechanism is right and the bear framing on magnitude is unprovable, by design. What can be said is that the risk is asymmetric: an extension delivers continuity rather than upside, while a lapse delivers a headwind of unknown size to the fastest-growing part of the book. That asymmetry belongs in the multiple until January, and it is the primary reason this initiation is not a buy.
Debate: Has the Stock Already Repriced for a Better Business?
Bull view: The 46.6% year-to-date move reflects a genuinely re-rated business: labor normalized, contract labor at 4.2%, cash conversion approaching 50%, 9% annual share-count reduction, leverage in the lower half of target. At roughly 16x the midpoint of the raised FY25 EPS guide, an operator compounding mid-teens EPS is not expensive.
Bear view: That 16x is on an EPS number containing $250M to $350M of supplemental payment benefit, a 9% share-count tailwind and a hurricane-comparison benefit. Normalize those and the multiple on underlying earnings power is meaningfully higher, on a stock that has already advanced 46.6% and sits at 52-week highs with the largest 2026 variable unquantified.
Our take: The business is genuinely better than it was in 2023 and the labor improvement in particular is structural and underappreciated. But the re-rating has already happened, and it happened during a year in which policy was a tailwind. Paying a re-rated multiple for a business entering a year where the same policy channel turns from tailwind to unquantified headwind is not an attractive risk/reward. The muted 1.6% reaction to a 23% beat suggests the marginal buyer has reached the same conclusion.
Model Update Needed
| Item | Prior framework | Suggested | Reason |
|---|---|---|---|
| FY25 revenue | n/a (initiation) | $75.75B (guide midpoint) | Nine-month actual $56.087B plus implied Q4 of ~$19.66B |
| FY25 Adjusted EBITDA | n/a | $15.45B (guide midpoint) | Raised guide; implies Q4 of ~$4.00B |
| FY25 diluted EPS | n/a | $27.50 (guide midpoint) | Implies Q4 of roughly $7.27 against nine-month $20.23 |
| Same-facility volume growth | n/a | 2.0–2.5% for FY26 | Low end of company's 2–3% range pending EPTC resolution |
| Underlying rate growth (ex-supplemental) | n/a | ~3.0–3.5% | Half of the 6.6% same-facility print was supplemental payments |
| Supplemental payment net benefit | n/a | Hold flat in FY26; do not grow | Pending state approvals unguided; Q4 already guided down $120M YoY |
| Salaries and benefits | n/a | 43.5–44.0% of revenue | Structural improvement; contract labor normalized at 4.2% of labor |
| Professional fees | n/a | +8–11% growth | No management plan disclosed to converge toward inflation |
| Diluted share count | n/a | ~232M exiting FY25, declining 5–7% in FY26 | $3.256B authorization remaining; slower than 2025's elevated pace |
| Q4 hurricane-market recovery | n/a | Haircut the $100M to $60–80M | Three quarters produced ~$0; entire target back-loaded |
| FY25 free cash flow | n/a | Adjust down ~$1.3B for tax-payment timing | Deferral reverses in Q4 |
Valuation framework. At the October 24 close of $447.04, HCA trades at roughly 16.3x the midpoint of the raised FY25 diluted EPS guide of $27.00 to $28.00. That multiple is not demanding for a business generating 20.2% Adjusted EBITDA margins with a shrinking share count. The complication is what sits inside the E: the FY25 number carries $250M to $350M of supplemental-payment benefit versus 2024, a full-year share-count reduction, and an easy hurricane comparison. Applying a 15x to 17x range to a normalized FY26 earnings power that holds supplemental payments flat and assumes low-end volume growth produces a fair value band of roughly $430 to $500, a midpoint of about $465, implying roughly +4% from the current $447.04. The band is deliberately wide because the largest 2026 input is a legislative outcome, not an operating assumption, and it narrows materially once January guidance lands.
Thesis Scorecard Post-Earnings
This is our initiation on HCA, so the table below establishes the pillars rather than grading them against a prior standing thesis. Each carries an initial status that subsequent quarters will be scored against.
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: Structural labor normalization defends margin through a demand shock | Confirmed | S&B at 43.6% of revenue (down 140bps YoY), contract labor flat at 4.2% of total labor, management states capacity is no longer staffing-constrained |
| Bull #2: Scale, network density and service diversification sustain 2–3% volume growth | Confirmed | 18 consecutive quarters of volume growth; same-facility equivalent admissions +2.4% despite an estimated 50bp respiratory drag; length of stay down to 4.660 days creates capacity headroom |
| Bull #3: Cash generation plus low leverage funds a durable buyback that compounds EPS | Confirmed | $2.498B repurchased in the quarter, share count down 9.1% YoY, leverage in the lower half of the target range, $6.076B of facility availability |
| Bear #1: EPTC expiration removes the fastest-growing slice of the commercial book | Emerging | Exchange equivalent admissions +8% vs. total commercial +3.7%; company will not disclose exposure size; management explicitly declined to size the 2026 impact three times |
| Bear #2: Earnings quality depends on Medicaid supplemental payments the company does not control | Emerging | ~$240M of the $603M YoY Adjusted EBITDA increase; $250M of the $450M guidance raise; Q4 already guided down $120M YoY on this line |
| Bear #3: Professional fees are a structural cost problem without a disclosed plan | Emerging | Same-facility professional fees +11% YoY at roughly 24% of other operating expenses; Valesco economics not broken out |
Overall: Thesis established. Three bull pillars confirmed on this quarter's evidence, all three of them operating rather than policy-driven, which is the encouraging part. Three bear points open, two of which (coverage policy and supplemental payments) route through the same federal channel and will be resolved or escalated together in January.
Action: Hold. Initiate a position on weakness toward the low $400s, where the fair-value band offers a genuine margin of safety against an unquantified policy outcome. At $447 the risk/reward is balanced and the calendar, rather than the business, is the binding constraint. The Q4 call in late January carries FY26 guidance, the EPTC resolution, the hurricane-market recovery verdict, and the promised resiliency update, which makes it the single most information-dense catalyst in the coverage.